Sidney Wolfe
Cetus Corporation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sidney Wolfe.
Journal of Clinical Immunology | 1986
Mark Allegretta; Michael B. Atkins; Roy A. Dempsey; Edward C. Bradley; Michael Konrad; Ann Childs; Sidney Wolfe
Approximately 65% (11/17) of cancer patients participating in an ongoing Phase I clinical trial with recombinant interleukin-2 developed nonneutralizing serum IgG anti-interleukin-2 antibodies within 1 month of initiating therapy. These antibodies could be detected using any of several standard techniques including immunoblots and enzyme-linked immunosorbent assays. Western blot analysis and retention experiments with protein A-Sepharose indicate that the antibodies are specific for interleukin-2. The interleukin-2 mutein utilized in this clinical trial (des-ala-ser125 r-IL-2) differs from the major species of the human T cell-derived lymphokine in that it lacks the N-terminal alanine of the native molecule, is not glycosylated, and possesses a serine-cysteine substitution at position 125. Another recombinant interleukin-2, identical to the mutein except that it retains the cysteine at position 125 (des-ala-cys125 r-IL-2), strongly competes with the mutein in competitive enzyme-linked immunosorbent assays, suggesting that the amino acid substitution is not responsible for the recognition of the molecule by serum antibodies. Conversely, nonrecombinant T cell-derived interleukin-2 fails to compete in these assays and is not retained by protein A-Sepharose columns when mixed with high-titer antiserum. These results suggest that the anti-interleukin-2 serum antibodies generated in the course of treatment do not react with the nonrecombinant lymphokine but recognize epitopes peculiar to recombinant forms which are not dependent on the amino acid substitution at position 125. The failure of the antibodies to neutralize the biological activity of recombinant interleukin-2 (IL-2) in lymphocyte proliferation assays and to bind to the native lymphokine suggests that they may not affect IL-2-dependent cellular immune functionsin vivo.
Archive | 1989
Sidney Wolfe; Glenn Dorin; John T. Davis; Flint Smith; Amy Lim; Robert Weissburg
Archive | 1986
Glenn Dorin; Wolfgang Helmut Hanisch; James William Thomson; Sidney Wolfe; Leo S. Lin
Archive | 1985
Ze Ev Shaked; Sidney Wolfe
Archive | 1986
Leo S. Lin; Glenn Dorin; Ralph Yamamoto; Wolfgang Helmut Hanisch; James William Thomson; Sidney Wolfe
Archive | 1984
Ze've Shaked; Sidney Wolfe
Archive | 2001
Sidney Wolfe; Irina Esikova; Susan Babuka; Bret A. Shirley; Dennis Fordham
Archive | 2000
Irina Esikova; Sidney Wolfe; James William Thomson; Hora Maninder
Archive | 2000
Irina Esikova; Sidney Wolfe; James William Thomson; Hora Maninder
Archive | 2000
Irina Esikova; Sidney Wolfe; James William Thomson; Hora Maninder